Journal of Transplantation / 2009 / Article / Tab 2

Research Article

Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance

Table 2

Antiviral therapy timing, duration, dose reductions, growth factor use, and virologic outcomes in treated group 1 and 2 patients.

VariableGroup 1 ISH positive Group 2 ISH negative

Pegylated IFN100%86%.23
Dose reduction40%33%.73
Growth factors used80%73%.70
LT-Treatment interval, months6 ± 39 ± 7.35
Treatment duration at ISH biopsy months13 ± 610 ± 4.24
Total treatment duration24 ± 1014 ± 5.001
EVR90%86%.75
ETR90%*100%NA
SVR80%*60%.29

patient was still on treatment at last follow up.